GNS Unveils Platform to Predict New Therapy’s Likely Success in Real World at ISPOR
Click here to receive MS news via e-mail GNS Healthcare is presenting a data-driven causal machine learning solution, called Efficacy to Effectiveness, designed to predict how potential therapies will actually perform in distinct populations. The data, being released today at ISPOR 2016, used pre-launch data from a study comparing Gilenya (fingolimod) and other multiple sclerosis (MS) therapies to build and validate causal models that estimate Gilenya’s likely performance on the market. The platform, demonstrated in collaboration with Novartis (the developer of Gilenya) and Harvard University, is designed to help inform pharmaceutical makers’ pre-launch market strategies, and to create evidence supporting the benefits of a new therapy to specific groups of patients. “Clinical trials are the gold standard for assessing efficacy, but the real world — where a drug is in competition with other therapies and is no longer constrained to a well-defined trial…
Link to Full Article: GNS Unveils Platform to Predict New Therapy’s Likely Success in Real World at ISPOR
GNS Unveils Platform to Predict New Therapy's Likely Success in Real World at ISPOR
